halobetasol
Trade name: ultravate
Approved
Dec 27, 1990
Halobetasol Propionate is the propionate salt form of halobetasol, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictor activities. Halobetasol, a topical steroid, diffuses across cell membranes to interact with cytoplasmic corticosteroid receptors located in both the dermal and intradermal cells, thereby activating gene expression of anti-inflammatory proteins mediated via corticosteroid receptor response element. Specifically, this agent induces phospholipase A2 inhibitory proteins, which inhibit the release of arachidonic acid, thereby inhibiting the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes. As a result, halobetasol reduces edema, erythema, and pruritus through its cutaneous effects on vascular dilation and permeability. The initial interaction, however, is due to the drug binding to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. — NCATS
Clinical trial activity
26 trials · 18 clinical orgs · 1 marketing orgs
Earliest trial started Dec 1, 2003 (NCT00865267)
Timeline
1990s
- Dec 27, 1990
Bristol-Myers Squibb — Earliest FDA Approval
- Dec 27, 1990
Bristol-Myers Squibb — NDA Organization
2010s
- Jan 1, 2015
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Glucocorticoid receptorAGONIST
NR3C1 agonist
Approval history
- approvedDec 27, 1990
Chemistry & pharmacology
SMILES
C[C@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl- Mol. weight
- 428.897 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaUlobetasol ↗
- NCATS9P6159HM7T ↗
- ChEMBLCHEMBL1200908 ↗
Also known as
- 21-chloro diflorasone
- 21-chloro diflorasone
- 6 alpha-fluoroclobetasol 17-propionate
- 6-fluoroclobetasol 17-propionate
- bmy-30056
- bmy-30056
- cgp 14458
- cgp 14 458
- cgp-14458
- cgp-14458
- cgp-14458
- halobetasol
- halobetasol
- halobetasol
- halobetasol
- halobetasol
- halobetasol propionate
- halobetasol propionate
- halobetasol propionate
- idp-122
- ulobetasol
- ulobetasol
- ulobetasol
- ulobetasol
- ulobetasol
- ulobétasol
- ulobétasol
- ulobetasolum
- ulobetasolum
- ultravate
- ultravate
- ultravate
- ultravate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06042647 | Phase 4 | Jul 13, 2023 | Dermatology Consulting Services, High Point NC |
| NCT05872256 | Phase 4 | Jun 1, 2023 | Dermatology Consulting Services, High Point NC |
| NCT05608499 | Phase 3 | Oct 4, 2022 | Bausch Health Companies, Icahn School of Medicine at Mount Sinai |
| NCT05348200 | Phase 2 | Apr 22, 2022 | Citius Pharmaceuticals, Therapeutics, Inc. |
| NCT05203315 | Phase 3 | Jan 17, 2022 | Austin Institute for Clinical Research |
| NCT05282771 | Early Phase 1 (Phase 1) | Apr 16, 2021 | Catawba Clinical Research, Taro Pharmaceuticals |
| NCT04571151 | Phase 4 | Jan 31, 2021 | University of Tehran |
| NCT04720105 | Phase 4 | Nov 19, 2020 | Bausch Health Companies, Icahn School of Medicine at Mount Sinai |
| NCT04119102 | Phase 4 | Oct 1, 2019 | Bausch Health Companies, Windsor Dermatology |
| NCT03992261 | Phase 4 | Jun 14, 2019 | Mayne Pharma |
| NCT03988439 | Phase 4 | Jun 8, 2019 | Bausch Health Companies |
| NCT03987763 | Phase 4 | Jun 8, 2019 | Bausch Health Companies |
| NCT03298581 | Phase 2 | Nov 1, 2017 | Novum Pharmaceutical Research Services, Sun Pharmaceuticals |
| NCT03245385 | Phase 2 | Jun 29, 2017 | Novum Pharmaceutical Research Services, Sun Pharmaceuticals |
| NCT03212963 | Phase 4 | Mar 21, 2017 | Sun Pharmaceuticals, Therapeutics, Inc. |
| NCT02785185 | Phase 2 | Jun 1, 2016 | Bausch Health Companies |
| NCT02785172 | Phase 2 | Apr 1, 2016 | Bausch Health Companies |
| NCT02514577 | Phase 3 | Nov 20, 2015 | Bausch Health Companies |
| NCT02515097 | Phase 3 | Nov 10, 2015 | Bausch Health Companies |
| NCT01610596 | Phase 2 | Nov 1, 2011 | Therapeutics, Inc. |
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bausch Health Companies | For profit | 9 | 6 | 3 | 2015 |
| Therapeutics, Inc. | For profit | 4 | 2 | 2 | 2010 |
| Sun Pharmaceuticals | For profit | 3 | 3 | 2 | 2017 |
| Actavis | For profit | 2 | 2 | 1 | 2003 |
| Dermatology Consulting Services, High Point NC | Academic/Hospital | 2 | 2 | 1 | 2023 |
| DermTech International | For profit | 2 | 0 | 1 | 2003 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Novum Pharmaceutical Research Services | For profit | 2 | 0 | 1 | 2017 |
| Austin Institute for Clinical Research | For profit | 1 | 1 | 1 | 2022 |
| Azidus | For profit | 1 | 1 | 1 | 2008 |
| Catawba Clinical Research | For profit | 1 | 0 | 1 | 2021 |
| Citius Pharmaceuticals | For profit | 1 | 1 | 1 | 2022 |
| Mayne Pharma | For profit | 1 | 1 | 1 | 2019 |
| Patel, Rita Vikram, M.D. | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Taro Pharmaceuticals | For profit | 1 | 1 | 1 | 2021 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2009 |
| University of Tehran | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Windsor Dermatology | Academic/Hospital | 1 | 1 | 1 | 2019 |
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bristol-Myers Squibb | For profit | NDA | Dec 27, 1990 |